Pipoxolan 是一种具有口服活性的平滑肌松弛剂、抗炎剂和抗癌剂,可调控 PI3K/AKT 信号通路并降低 Ras/MEK/p-ERK、MMP-2 和 MMP-9 水平,抑制促炎转录因子通路、激活 Nrf2/HO-1 并抑制促炎介质的生成,诱导 ROS 生成、内源性线粒体凋亡 (Apoptosis) 和 G0/G1 细胞周期阻滞,缩小脑梗死面积并抑制内膜增生,可用于脑缺血、内膜增生、口腔鳞状细胞癌、白血病和肺癌的相关研究。
产品编号: MS-F60016 CAS No.: 23744-24-3 分子式: C22H25NO3 分子量: 351.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Pipoxolan 是一种具有口服活性的平滑肌松弛剂、抗炎剂和抗癌剂,可调控 PI3K/AKT 信号通路并降低 Ras/MEK/p-ERK、MMP-2 和 MMP-9 水平,抑制促炎转录因子通路、激活 Nrf2/HO-1 并抑制促炎介质的生成,诱导 ROS 生成、内源性线粒体凋亡 (Apoptosis) 和 G0/G1 细胞周期阻滞,缩小脑梗死面积并抑制内膜增生,可用于脑缺血、内膜增生、口腔鳞状细胞癌、白血病和肺癌的相关研究。

生物实验数据

生物活性 Pipoxolan is an orally active smooth muscle relaxant, anti-inflammatory agent, and anticancer agent that modulates the PI3K/AKT signaling pathway and reduces Ras/MEK/p-ERK, MMP-2, and MMP-9 levels, inhibits pro-inflammatory transcription factor pathways, activates Nrf2/HO-1, and suppresses the production of pro-inflammatory mediators, induces ROS generation, intrinsic mitochondrial apoptosis (Apoptosis), and G0/G1 cell cycle arrest, reduces cerebral infarct size, and inhibits intimal hyperplasia, and can be used for research related to cerebral ischemia, intimal hyperplasia, oral squamous cell carcinoma, leukemia, and lung cancer.
IC50 & Target

MMP-9

 

MMP-2

 

HO-1

 

体外研究
(In Vitro)

Pipoxolan (5-15 µM; 24-72 h) 可在 24、48 和 72 小时内以剂量依赖方式强效抑制 PDGF-BB 刺激的 A7r5 血管平滑肌细胞迁移。
Pipoxolan (5-15 µM; 48 h pre-treatment; 8 hr migration period) 在 Transwell 实验中可抑制 PDGF-BB 刺激的 A7r5 血管平滑肌细胞迁移,最高浓度下的抑制率达 76.5%。
Pipoxolan (5-15 µM; 48 h) 可下调 PDGF-BB 刺激的 A7r5 血管平滑肌细胞中 Ras、MEK、p-ERK、MMP-2 和 MMP-9 的蛋白水平,其中在 15 µM 浓度下 p-ERK 的降低幅度最大 (75%)。
Pipoxolan (1.6-100 μg/mL; 24 h) 在体外对 TW206、HSC-3 和 Cal-27 细胞具有细胞毒性,其 IC50 值分别为 13.13 μg/mL、42.28 μg/mL 和 52.69 μg/mL,且 TW206 和 HSC-3 细胞比 Cal-27 细胞更敏感。
Pipoxolan (20 μg/mL; 2-6 h) 以时间依赖的方式诱导 TW206 口腔鳞状细胞癌细胞发生凋亡,在以 20 μg/mL Pipoxolan 处理 2 h 时可检测到凋亡,处理 6 h 时凋亡水平达到峰值。
Pipoxolan (4-32 μM;预处理 1 h;LPS 孵育 24 h) 在 LPS 刺激的 RAW 264.7 小鼠巨噬细胞中无显著细胞毒性。
Pipoxolan (4-32 μM; 1 h pretreatment; 24 h LPS incubation) 可剂量依赖性地抑制 RAW 264.7 小鼠巨噬细胞中 LPS 诱导的亚硝酸盐生成,在 32 μM 浓度下抑制率达 68.24%。
Pipoxolan (4-32 μM; 1 h pretreatment; 24 h LPS incubation) 可剂量依赖性地抑制 RAW 264.7 小鼠巨噬细胞中 LPS 诱导的 PGE2、TNF-α 和 IL-6 的产生,在 32 μM 时对三者的最大抑制率分别为 90.73% (PGE2)、90% (TNF-α) 和 95.27% (IL-6)。
Pipoxolan (1.6-50 μg/mL; 24 h) 可强效抑制白血病 HL-60 细胞、U937 细胞和 K562 细胞的增殖,作用 24 h 后其对 HL-60 细胞的 IC50 为 6.25 μg/mL,对 U937 细胞的 IC50 为 12.5 μg/mL,对 K562 细胞的 IC50 为 25 μg/mL;而在浓度高达 50 μg/mL 时,该化合物对正常外周血单个核细胞 (PBMC) 无细胞毒性。
Pipoxolan (1.6-25 μg/mL; 2-48 h) 以时间依赖的方式将人白血病 HL-60 细胞阻滞于 G0/G1 期,在 6.25 μg/mL 作用 48 h 时阻滞比例达 62.0%,并在 24 h 后诱导亚 G1 期凋亡细胞呈剂量依赖性累积。
Pipoxolan (3.2-25 μg/mL; 15 min-24 h) 可在白血病 HL-60 细胞中诱导快速、时间及浓度依赖性的细胞内 ROS 生成,这对其凋亡活性至关重要,因为 NAC 预处理可同时阻断 ROS 生成与细胞凋亡。
Pipoxolan (2-10 μg/mL; 24 h) 在 5 和 10 μg/mL 浓度下孵育 24 h 后可显著抑制 CL1-5 肺腺癌细胞的增殖。
Pipoxolan (2-10 μg/mL; 24 h) 在 2、5 或 10 μg/mL 浓度下孵育 24 h 后,不会诱导 CL1-5 或 CL1-0 肺腺癌细胞发生凋亡。

Cell Migration Assay

Cell Line: A7r5 vascular smooth muscle cells (VSMCs)
Concentration: 5-15 µM
Incubation Time: 24, 48, 72 hr
Result: Attenuated PDGF-BB-stimulated A7r5 cell migration in a dose-dependent manner at all time points tested.
Significantly reduced relative migration compared to PDGF-BB-only controls.
Exhibited the highest inhibition at the 15 µM concentration across all time points.

Cell Migration Assay

Cell Line: A7r5 vascular smooth muscle cells (VSMCs)
Concentration: 5-15 µM
Incubation Time: 48 hr pre-treatment; 8 hr migration period
Result: Significantly reduced the number of PDGF-BB-stimulated A7r5 cells migrating across the membrane.
Achieved percent inhibition of 46.2% at 5 µM, 62.2% at 10 µM, and 76.5% at 15 µM compared to PDGF-BB-only controls.

Western Blot Analysis

Cell Line: A7r5 vascular smooth muscle cells (VSMCs)
Concentration: 5-15 µM
Incubation Time: 48 h
Result: Reduced Ras protein levels by 21% at 5 µM, 24.75% at 10 µM, and 24% at 15 µM compared to PDGF-BB-only controls.
Reduced MEK protein levels by 21.67% at 5 µM, 21% at 10 µM, and 26.67% at 15 µM compared to PDGF-BB-only controls.
Reduced p-ERK protein levels by 50.33% at 5 µM, 51.67% at 10 µM, and 75% at 15 µM compared to PDGF-BB-only controls.
Reduced MMP-2 protein levels by 12.4% at 10 µM and 24.4% at 15 µM compared to PDGF-BB-only controls.
Reduced MMP-9 protein levels by 39.4% at 5 µM, 45.4% at 10 µM, and 36.6% at 15 µM compared to PDGF-BB-only controls.

Cell Viability Assay

Cell Line: human oral squamous cell carcinoma (OSCC) TW206, HSC-3 cells; human head and neck squamous cell carcinoma (HNSCC) Cal-27 cells
Concentration: 1.6, 3.2, 6.25, 12.5, 25, 50, 100 μg/mL
Incubation Time: 24 h
Result: Dose-dependently reduced cell viability in all three cell lines.
Reached IC50 values of 13.13 μg/mL for TW206 cells, 42.28 μg/mL for HSC-3 cells, and 52.69 μg/mL for Cal-27 cells.
Showed greater cytotoxicity to TW206 and HSC-3 cells than Cal-27 cells.

Western Blot Analysis

Cell Line: human OSCC TW206 and HSC-3 cells
Concentration: 20 μg/mL (TW206 cells); 50 μg/mL (HSC-3 cells)
Incubation Time: 2, 4, 8, 12, 24, 48 h
Result: Caused time-dependent increases in cytosolic cytochrome c, active caspase-9, active caspase-3, and cleaved PARP in HSC-3 cells, and did not alter caspase-8 expression.
Increased pro-apoptotic BAX protein expression and decreased anti-apoptotic BCL2 protein expression in both TW206 and HSC-3 cells after 24 h.
Caused time-dependent decreases in PI3K and phosphorylated AKT (pAKT) levels in both cell lines, with significant suppression after 24 h.

ELISA Assay

Cell Line: RAW 264.7 murine macrophage cells
Concentration: 4-32 μM
Incubation Time: 1 h pretreatment; 24 h LPS incubation
Result: Dose-dependently inhibited LPS-induced production of PGE2, TNF-α, and IL-6.
Inhibited PGE2 production by 90.73%, TNF-α production by 90%, and IL-6 production by 95.27% at 32 μM compared to LPS-only treated cells.
Showed statistically significant inhibition at all tested concentrations for each cytokine.

Immunofluorescence

Cell Line: RAW 264.7 murine macrophage cells
Concentration: 32 μM
Incubation Time: 1 h pretreatment; 6 h LPS incubation
Result: Promoted LPS-induced translocation of Nrf2 from the cytoplasm to the nucleus, as visualized by increased nuclear Nrf2 fluorescence compared to LPS-only treated cells.

Cell Cycle Analysis

Cell Line: human leukaemia HL-60 cells
Concentration: 1.6, 3.2, 6.25, 12.5, 25 μg/mL (24 h incubation); 6.25 μg/mL (2-48 h incubation)
Incubation Time: 2, 6, 12, 24, 48 h
Result: Induced significant apoptosis (sub-G1 hypodiploid cells) with 6.25 μg/mL for 24 h.
Caused dose-dependent increases in sub-G1 cells at 12.5, 25 μg/mL after 24 h.
Caused time-dependent accumulation of cells in the G0/G1 phase: 48.7% at 12 h, 58.1% at 24 h, and 62.0% at 48 h, all statistically significant compared to controls.
体内研究
(In Vivo)

Pipoxolan (10-30 mg/kg;口服;缺血前 1 小时单次) 可剂量依赖性减轻雄性 Sprague-Dawley 大鼠的脑缺血再灌注损伤,其中 30 mg/kg (口服) 可使脑梗死面积减少 73.43%,裂解型 Caspase-3 阳性细胞减少 63.44%。
Pipoxolan (10-30 mg/kg;口服;每日;于结扎当日开始,持续 28 天) 可剂量依赖性地减轻雄性 ICR 小鼠颈动脉结扎诱导的内膜增生,其中 30 mg/kg 可使 I/M 比值降低 47.20%,并使 PCNA 阳性细胞受到 62.40%的抑制。

Animal Model: Sprague-Dawley (male, 225-275 g, transient focal cerebral ischemia-reperfusion model)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; single dose 1 hour pre-ischemia
Result: Reduced cerebral infarction area by 43.18%, neurological deficit score by 31.25%, TUNEL-positive cells by 31.25%, and cleaved caspase-3-positive cells by 37.18%.
Reduced cerebral infarction area by 73.43%, neurological deficit score by 46.88%, TUNEL-positive cells by 46.88%, and cleaved caspase-3-positive cells by 63.44%.
Did not alter mean arterial pressure or cerebral blood flow compared to controls.
Animal Model: ICR (male, 20-25 g, left common carotid artery ligation-induced model)
Dosage: 10 mg/kg; 30 mg/kg
Administration: p.o.; daily; 28 days starting on the day of ligation
Result: Reduced the intima/media (I/M) ratio by 24.21% and inhibited PCNA-positive cells by 42.11%.
Reduced the intima/media (I/M) ratio by 47.20% and inhibited PCNA-positive cells by 62.40%.

化学信息

分子量 351.45
分子式 C22H25NO3
CAS No. 23744-24-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础